Barclays raised the firm’s price target on Protagonist Therapeutics (PTGX) to $113 from $108 and keeps an Overweight rating on the shares post the Q4 report.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PTGX:
- Protagonist Therapeutics: Late-Stage Pipeline Strength and Rusfertide Economics Drive Buy Rating and $100 Price Target
- Protagonist Therapeutics price target raised to $117 from $80 at H.C. Wainwright
- Protagonist Therapeutics: Advancing Multi-Asset Inflammation and Obesity Pipeline with Strong Cash Runway Supports Buy Rating
- Protagonist Therapeutics Highlights Diversified Pipeline and Partnerships
- Advancing, De-Risked Pipeline and Near-Term Regulatory Catalysts Underpin Protagonist Therapeutics Buy Rating